Navigation Links
Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
Date:12/3/2013

SAN DIEGO, Dec. 3, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced a regulatory update after receiving feedback from the U.S. Food and Drug Administration (FDA) on the development of quizartinib (AC220), the Company's lead drug candidate, for the treatment of relapsed/refractory acute myeloid leukemia (AML).

Based on feedback from the FDA, the Company continues to move forward with its baseline plan to conduct a randomized, controlled Phase 3 clinical trial in relapsed/refractory FLT3-ITD positive AML patients with an overall survival endpoint as the basis for the potential initial approval of quizartinib.  The Company is continuing to work with the FDA to refine the appropriate starting dose for the Phase 3 trial. 

The Company has been in dialogue with the FDA related to acceptance of a novel surrogate endpoint that could support accelerated approval based upon the results of the Company's Phase 2 and Phase 2b trials.  The FDA informed the Company it does not agree that complete remission with incomplete hematologic recovery (CRi) represents a surrogate endpoint reasonably likely to predict clinical benefit.  Based on the FDA's current position, the Company does not plan at this time to submit a NDA for accelerated approval of quizartinib based on the Phase 2 and 2b clinical trial data.

"We remain committed to moving quizartinib through its late stage development as expeditiously as possible, given the limited treatment options for FLT3 ITD positive AML patients who have relapsed or who are refractory to prior treatments.  We will continue to work with the clinical community and the FDA to achieve this goal," said

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ambit Biosciences to Announce Third Quarter 2013 Financial and Operating Results and Conference Call
2. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
3. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
4. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
5. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
6. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
7. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
10. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
11. Neodyne Biosciences Announces Issuance of U.S. Patent for Devices and Methods for Dressing Applicators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014 HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that it expects revenues for the fourth ... expected full-year 2013 revenues to approximately $208 million. ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
(Date:4/23/2014)... LAFAYETTE, Ind. - Purdue University researchers have developed a ... living cell by using tiny gold particles with tails ... professor of agricultural and biological engineering, used gold nanoparticles ... known as BRCA1 messenger RNA splice variants, which can ... number of these mRNA splice variants in a cell ...
(Date:4/23/2014)... area of the gastro-intestinal tract has long been considered ... at the Sahlgrenska Academy have used refined microscopic techniques ... inner surface of the gastro-intestinal tract is only as ... Fndriks. , The digestive tract, which passes from the ... has a length of about 5 meters in a ...
(Date:4/23/2014)... detection methods that can rapidly screen a large ... cell inside that population has been seriously lacking," ... In the Royal Society of Chemistry journal ... and his coworkers have developed a novel technique ... ( Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, ...
(Date:4/23/2014)... and vegetables are often displayed in the popular ... also plenty of high-sugar foods. A new study ... is portrayed in children,s TV programmes as well ... dietary habits and weight status. , Steingerdur Olafsdottir,s ... in the popular Swedish children,s TV show Bolibompa. ...
(Date:4/23/2014)... led by a researcher from the Cancer Science Institute ... Singapore has identified the cancer specific stem cell which ... of developing new drugs for the treatment of this ... group, led by Dr Chan Shing Leng, Research Assistant ... that a cancer-specific variant of a cell surface protein, ...
Breaking Medicine News(10 mins):Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3
... abstract that will be presented on Wednesday at SLEEP ... Sleep Societies (APSS), finds a link between normal sleep ... Ancoli-Israel, PhD, of the University of California at San ... of age or older. Reports of use of ...
... 11 DaVita Inc., a leading,provider of kidney ... and disease (CKD), recently announced that Debbie Benner, ... DaVita(R) and Mary,Burgess, RD, Grant Program Manager for ... abstracts at the XIV International Congress on,Nutrition and ...
... first time, UCLA researchers have discovered that people with ... help store memory. Reported in the June 27 edition ... importance of early detection of the disorder, which afflicts ... Sleep apnea occurs when a blocked airway repeatedly halts ...
... nonprofit organization, has announced it is offering free,step-by-step assistance to uninsured ... its mission to improve the overall,health of Americans throughout the United ... sites or,calling its toll-free numbers:, -- For English: ... ...
... SHANGHAI, China, June 10 /Xinhua-PRNewswire/ -- Fresenius Medical ... in the Chinese,province of Sichuan. In addition to ... of $1.1 million in both cash and material ... by the natural disaster.,Fresenius Medical Care is providing ...
... workers revive unconscious passenger, SACRAMENTO, Calif., June ... saved the life of a 53-year-old,passenger on their ... The trio was among a group of ... to attend a contract bargaining session with their,employer, ...
Cached Medicine News:Health News:Normal sleep linked to successful aging 2Health News:DaVita Dietitians to Speak at the International Congress on Nutrition and Metabolism in Renal Disease in France 2Health News:Memory loss linked to common sleep disorder 2Health News:Memory loss linked to common sleep disorder 3Health News:The CoverMe Foundation Offers Free, Step-By-Step Assistance to Connect Uninsured with Free or Reduced-Cost Health Care 2Health News:Fresenius Medical Care Supports Chinese Earthquake Victims 2Health News:UHW Members Save Man's Life On Flight 2
Radiopaque markers indicate the proximal and distal ends of the balloon. Supplied sterile in peel-open packages. Intended for one-time use....
... Ureteral Access Sheath, you can have all ... - plus an entirely new level of ... designed with a proprietary dual lumen design, ... channel for a variety of procedural steps ...
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
... Fr Straight Channel; 33 or 42 cm ... Operating Ureteroscopes offer a small distal diameter ... to the ureter for diagnosis and treatment. ... ideal for large operating instruments, mechanical (Lithoclast) ...
Medicine Products: